Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".
APA
Kim HD, Ryu MH, Kang YK (2025). Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".. Journal for immunotherapy of cancer, 13(5). https://doi.org/10.1136/jitc-2025-012332
MLA
Kim HD, et al.. "Author response to comment on "Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer".." Journal for immunotherapy of cancer, vol. 13, no. 5, 2025.
PMID
40447315
같은 제1저자의 인용 많은 논문 (5)
- Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
- Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
- Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy.
- Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy.
- Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer.